CLEC9A and cancer: Likewise, other studies in ovarian cancer indicate that the functional lack of 141+ DCs precursors is associated with a worse prognosis (18) and a study highlights that the administration of 141+ Clec9a+ DC stimulates CD8 T lymphocytes in Willis tumour and concludes that it is a promising candidate of immunotherapy in malignant neoplasms (19).